Gilead Sciences, Inc. (GILD) stock has gained 6.32% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.
Gilead Sciences, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on GILD!
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With GILD Stock Today?
Gilead Sciences, Inc. (GILD) stock is up 1.12% while the S&P 500 has fallen -0.05% as of 3:37 PM on Tuesday, Dec 5. GILD is higher by $0.88 from the previous closing price of $78.34 on volume of 3,430,131 shares. Over the past year the S&P 500 has gained 14.22% while GILD has fallen -9.96%. GILD earned $4.66 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 16.96.
To screen for more stocks like Gilead Sciences, Inc. click here.
More About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Click Here to get the full Stock Report for Gilead Sciences, Inc. stock.